Next Article in Journal
Overlapping ATP2C1 and ASTE1 Genes in Human Genome: Implications for SPCA1 Expression?
Previous Article in Journal
Nuclear Factor-κB (NF-κB) Regulates the Expression of Human Testis-Enriched Leucine-Rich Repeats and WD Repeat Domain Containing 1 (LRWD1) Gene
Previous Article in Special Issue
NotI Microarrays: Novel Epigenetic Markers for Early Detection and Prognosis of High Grade Serous Ovarian Cancer
Int. J. Mol. Sci. 2013, 14(1), 640-673; doi:10.3390/ijms14010640
Review

Ovarian Cancer: In Search of Better Marker Systems Based on DNA Repair Defects

,
,
 and *
Received: 27 August 2012; in revised form: 14 December 2012 / Accepted: 24 December 2012 / Published: 4 January 2013
(This article belongs to the Special Issue Cancer Molecules in Ovarian Cancer 2012)
View Full-Text   |   Download PDF [798 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: Ovarian cancer is the fifth most common female cancer in the Western world, and the deadliest gynecological malignancy. The overall poor prognosis for ovarian cancer patients is a consequence of aggressive biological behavior and a lack of adequate diagnostic tools for early detection. In fact, approximately 70% of all patients with epithelial ovarian cancer are diagnosed at advanced tumor stages. These facts highlight a significant clinical need for reliable and accurate detection methods for ovarian cancer, especially for patients at high risk. Because CA125 has not achieved satisfactory sensitivity and specificity in detecting ovarian cancer, numerous efforts, including those based on single and combined molecule detection and “omics” approaches, have been made to identify new biomarkers. Intriguingly, more than 10% of all ovarian cancer cases are of familial origin. BRCA1 and BRCA2 germline mutations are the most common genetic defects underlying hereditary ovarian cancer, which is why ovarian cancer risk assessment in developed countries, aside from pedigree analysis, relies on genetic testing of BRCA1 and BRCA2. Because not only BRCA1 and BRCA2 but also other susceptibility genes are tightly linked with ovarian cancer-specific DNA repair defects, another possible approach for defining susceptibility might be patient cell-based functional testing, a concept for which support came from a recent case-control study. This principle would be applicable to risk assessment and the prediction of responsiveness to conventional regimens involving platinum-based drugs and targeted therapies involving poly (ADP-ribose) polymerase (PARP) inhibitors.
Keywords: ovarian cancer risk; early detection; DNA repair errors; functional biomarker; prediction of therapeutic responsiveness ovarian cancer risk; early detection; DNA repair errors; functional biomarker; prediction of therapeutic responsiveness
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Varga, D.; Deniz, M.; Schwentner, L.; Wiesmüller, L. Ovarian Cancer: In Search of Better Marker Systems Based on DNA Repair Defects. Int. J. Mol. Sci. 2013, 14, 640-673.

AMA Style

Varga D, Deniz M, Schwentner L, Wiesmüller L. Ovarian Cancer: In Search of Better Marker Systems Based on DNA Repair Defects. International Journal of Molecular Sciences. 2013; 14(1):640-673.

Chicago/Turabian Style

Varga, Dominic; Deniz, Miriam; Schwentner, Lukas; Wiesmüller, Lisa. 2013. "Ovarian Cancer: In Search of Better Marker Systems Based on DNA Repair Defects." Int. J. Mol. Sci. 14, no. 1: 640-673.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert